bullish
Sinopharm Group (1099.HK) 23H1 - Strong Growth Would Continue, but Profit Margin Is Under Pressure
421 Views05 Sep 2023 08:55
Sinopharm’s performance growth in 23H1 was satisfactory, which is expected to maintain in 23H2, leading to optimistic full year performance. However, profit margin would continue to be under pressure.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Sinopharm Group (1099.HK) 23H1 - Strong Growth Would Continue, but Profit Margin Is Under Pressure05 Sep 2023
- Pre-IPO BrainAurora Medical Technology - The Outlook Is Highly Uncertain01 Sep 2023
- China Healthcare Weekly (Aug.18) - TCM Formula Granules VBP, Global Financing Rebound, CR Sanjiu20 Aug 2023
- Sinopharm Group Co (1099.HK) - Double-Digit Growth Is Expected in 2023; Margins Have Room to Improve19 Apr 2023
x